SCHEMBL26625713

SCHEMBL26625713

O=C(CN1CCN(c2cc(C(=O)O)nc(Cl)n2)CC1)OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CASP1 P29466 2/20 0.40
CASP5 P51878 2/20 0.40
MAPT P10636 1/20 0.40
GRM5 P41594 1/20 0.39
NAPEPLD Q6IQ20 2/20 0.39
PIK3CB P42338 2/20 0.39
TMEM97 Q5BJF2 2/20 0.39
SIGMAR1 Q99720 2/20 0.39
ADRB1 P08588 1/20 0.39
HRH1 P35367 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
CASP4 P49662 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26624526 0.89 PRMT1 (0.43) ALDH1A1SMN1; SMN2NAPEPLDTMEM97SIGMAR1
SCHEMBL23702506 0.85 NAPEPLD (0.50) SMN1; SMN2MAPTGRM5NAPEPLDTMEM97
SCHEMBL26625339 0.80 NAPEPLD (0.35) CASP1MAPTGRM5NAPEPLDCYP1A2
SCHEMBL22402422 0.78 VEGFA (0.54) ALDH1A1SMN1; SMN2MAPTCYP1A2CYP2C9
SCHEMBL24251635 0.77 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL26620439 0.77 NAPEPLD (0.51) SMN1; SMN2MAPTGRM5NAPEPLDPIK3CB
SCHEMBL5174004 0.76 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL3569051 0.75 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2HRH3CYP1A2CYP2C9
SCHEMBL25001507 0.75 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2HRH3CYP1A2CYP2C9
SCHEMBL23702477 0.74 NAPEPLD (0.53) ALDH1A1SMN1; SMN2MAPTNAPEPLDTMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339910-A1 RAS INHIBITORS AND METHODS OF USING THE SAME JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2023-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339910-A1 RAS INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS ALDH1A1 3682/4885SMN1; SMN2 4027/4885CASP1 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.